ifosfamide
Not Tagged
['reecur', 'sarcoma']
high-dose ifosfamide has shown superior survival benefit over three other chemo regimens for patients with recurring or refractory primary ewing sarcoma in the practice-changing reecur trial at #asco22. 
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.